91 related articles for article (PubMed ID: 28485511)
1. Combination of Nexrutine and docetaxel suppresses NFκB-mediated activation of c-FLIP.
Zhang Y; Li L; Wang J; Cheng W; Zhang J; Li X; Zhang Z; Gong J; Ghosh R; Kumar AP; Xie J
Mol Carcinog; 2017 Oct; 56(10):2200-2209. PubMed ID: 28485511
[TBL] [Abstract][Full Text] [Related]
2. Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.
Yun H; Xie J; Olumi AF; Ghosh R; Kumar AP
Oncotarget; 2015 May; 6(13):11600-13. PubMed ID: 25816367
[TBL] [Abstract][Full Text] [Related]
3. Palmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP.
Hambright HG; Batth IS; Xie J; Ghosh R; Kumar AP
Mol Carcinog; 2015 Oct; 54(10):1227-34. PubMed ID: 25043857
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
5. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
6. A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer.
Tsai CH; Tzeng SF; Hsieh SC; Yang YC; Hsiao YW; Tsai MH; Hsiao PW
Sci Rep; 2017 Nov; 7(1):15624. PubMed ID: 29142311
[TBL] [Abstract][Full Text] [Related]
7. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
[TBL] [Abstract][Full Text] [Related]
8. Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells.
Muralimanoharan SB; Kunnumakkara AB; Shylesh B; Kulkarni KH; Haiyan X; Ming H; Aggarwal BB; Rita G; Kumar AP
Prostate; 2009 Apr; 69(5):494-504. PubMed ID: 19107816
[TBL] [Abstract][Full Text] [Related]
9. Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB.
Lee SY; Cho JS; Yuk DY; Moon DC; Jung JK; Yoo HS; Lee YM; Han SB; Oh KW; Hong JT
J Pharmacol Sci; 2009 Oct; 111(2):124-36. PubMed ID: 19834284
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
[TBL] [Abstract][Full Text] [Related]
12. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.
McCourt C; Maxwell P; Mazzucchelli R; Montironi R; Scarpelli M; Salto-Tellez M; O'Sullivan JM; Longley DB; Waugh DJ
Clin Cancer Res; 2012 Jul; 18(14):3822-33. PubMed ID: 22623731
[TBL] [Abstract][Full Text] [Related]
13. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
14. Pao Pereira Extract Suppresses Castration-Resistant Prostate Cancer Cell Growth, Survival, and Invasion Through Inhibition of NFκB Signaling.
Chang C; Zhao W; Xie B; Deng Y; Han T; Cui Y; Dai Y; Zhang Z; Gao J; Guo H; Yan J
Integr Cancer Ther; 2014 May; 13(3):249-58. PubMed ID: 24287876
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
El-Zawahry A; McKillop J; Voelkel-Johnson C
BMC Cancer; 2005 Jan; 5():2. PubMed ID: 15638938
[TBL] [Abstract][Full Text] [Related]
17. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
[TBL] [Abstract][Full Text] [Related]
18. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
[TBL] [Abstract][Full Text] [Related]
19. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
[TBL] [Abstract][Full Text] [Related]
20. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
[No Abstract] [Full Text] [Related]
[Next] [New Search]
